Voluntary guidance for the development of tissue-engineered products

Tissue Engineering

Volumn 4, Issue 3, 1998, Pages 239-266

  Omstead, Daniel R ^a   Baird, Lynn G ^b   Christenson, Lisa ^c   Du Moulin, Gary ^d   Tubo, Ross ^d   Maxted, Deirdre D ^a   Davis, James ^e   Gentile, Frank T ^a  

^a Reprogenesis Inc   (United States)

^b CytoTherapeutics Inc   (United States)

^c Medical Communications   (United States)

^d GENZYME CORPORATION   (United States)

^e IPS Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL;

BIOENGINEERING; BIOMEDICAL TECHNOLOGY ASSESSMENT; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SAFETY;

ANIMALS; ARTIFICIAL ORGANS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL PRODUCTS; BIOMEDICAL ENGINEERING; BIOPROSTHESIS; CELLS, CULTURED; CLINICAL TRIALS; COMMUNICABLE DISEASE CONTROL; FEMALE; HUMANS; MALE; MATERIALS TESTING; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; SAFETY; TISSUE DONORS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031667357     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.1998.4.239     Document Type: Review

References (55)

1. Piciolo, G.L., Helman, K.B., and Johnson, P.C. Meeting report: tissue engineered medical products standards: the time is ripe. Tissue Eng. 4, 5, 1998.
2. Annual Meeting of the American Society of Testing and Materials, Atlanta, May, 7, 1998.
3. Proposed Approach to Regulation of Cellular and Tissue-Based Products. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, 1997.
4. Guidance for Human Somatic Cell Therapy and Gene Therapy. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, 1998.
5. Spilker, B., and Cuatrecasa, P. Inside the Drug Industry. Barcelona: Prous Science Publishers, 1990.
6. Mathieu, M., ed. Biologics Development: A Regulatory Overview. Waltham, MA: Paraxel International Publishers, 1993.
7. Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 889, 1994.
8. Scharp, D.W., Swanson, C.J., Olack, B.J., Latta, P.P., Hegre, O.D., Doherty, E.J., Gentile, F.T., Flavin, K.S., Ansara, M.F., and Lacy, P.E. Viability of encapsulated human islets following subcutaneous implantation in type I and type II diabetic patients and normal controls. Diabetes 43, 1167, 1994.
9. Burgess, F.W., Goddard, M.B., Savavese, D., and Wilkinson, H. Subarachnoid bovine adrenal chromaffin cell implants for cancer pain management. APS Abstr. 54, 1996.
10. Points to Consider in Somatic Cell and Gene Therapy. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, 1993.
11. Points to Consider in the Characterization of Cell Lines to Produce Biologicals. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, 1993.
12. Points to Consider in the Collection, Processing, and Testing of Ex-Vivo-Activated Mononuclear Leukocytes for Administration to Humans. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, 1989.
13. Guidance on Applications for Products Comprised of Living Autologous Cells Manipulated Ex Vivo and Intended for Structural Repair on Reconstruction. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, May 1996.
14. Draft Document Concerning the Screening and Testing of Donors of Human Tissue Intended for Transplantation. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, June 1995.
15. Draft Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, August 1996.
16. Draft Guidance for the Submission of Chemistry, Manufacturing and Controls Information and Establishment Description for Autologous Somatic Cell Therapy Products. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, January 1997.
17. Rees, D.A., and Lloyd, C.W., eds. Cellular Controls in Differentiation. London: Academic Press, 1981.
18. Pollack, R., ed. Readings in Mammalian Cell Culture. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1975.
19. Benya, P.D., and Shaeffer, J.D. Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels. Cell 30, 215, 1982.
20. Fresjney, R.I. Culture of Animal Cells. 3rd ed. New York: John Wiley & Sons, 1994.
21. Herzenburg, L.A., Sweet, R.G., and Herzenburg, L.A. Fluorescence activated cell-sorting. Sci. Am. 234, 108, 1976.
22. Binette, F., McQuaid, D.P., Haudenschild, D.R., Yaeger, P.C., McPherson, J.M., and Tubo, R. Expression of a stable articular cartilage phenotype without evidence of hypertrophy by adult human articular chondrocytes in vitro. J. Orthop. Res. (in press).
23. Yaeger, P.C., Masi, T.L., Buck de Ortiz, J.L., Binette, F., Tubo, R., and McPherson, J.M. Synergistic action of transforming growth factor-beta and insulin-like growth factor-I induces expression of type II collagen and aggrecan genes in adult human articular chondrocyte. Exp. Cell Res. 237, 318, 1997.
24. Trask, B.J. Gene mapping by in situ hybridization. Curr. Opin. Genet. Dev. 1, 82, 1991.
25. Peppas, N.A. Biomaterials: interfacial phenomena and applications. In: Cooper, S.L., and Peppas, N.A., eds. Structure, Testing and Applications of Biomaterials. ACS Symposium Series, Washington, DC: ACS, 1983, p. 199.
26. Boch, B., and Hastings, G.W. Plastics in Surgery. Springfield, IL: Charles C. Thomas, 1967.
27. Stokes, K., and Cobain, K. Polyether polyurethans for implantable pacemaker leads. Biomaterials 3, 25, 1982.
28. Atala, A., Kim, W., Paige, K.T., Vacanti, C.H., and Retik, A.B. Endoscopic treatment of vesicoureteral reflux with a chondrocyte-alginate suspension. J. Urol. 152, 641, 1994.
29. Ziats, N.P., Miller, K.M., and Anderson, J.M. In vitro and in vivo interactions of cells with biomaterials. Biomaterials 9, 5, 1988.
30. Hench, L.L., and Ethridge, E.G. Biomaterials: An Interfacial Approach. New York: Academic Press, 1982.
31. Bakker, D., van Blitterswijk, C.A., Hesseling, S.C., Grote, J.J., and Daems, W.T. Effect of implantation site on phagocyte/polymer interaction and fibrous capsule formation. Biomaterials 9, 14, 1988.
32. Behling, C.A., and Spector, M. Quantitative characterization of cells at the interface of long-term implants of selected polymers. J. Biomed. Mater. Res. 20, 653, 1986.
33. Kordan, H.A. Localized interfacial forces resulting from implanted plastics as possible physical factors involved in tumor formation. J. Theor. Biol. 17, 1, 1967.
34. Behling, C.A., and Spector, M. Quantitative characterization of cells at the interface of long-term implants of selected polymers. J. Biomed. Mater. Res. 20, 653, 1986.
35. Inoue, T., Cox, J.E., Pilliar, R.M., and Melcher, A.H. Effect of the surface geometry of smooth and porous-coated titanium alloy on the orientation of fibroblasts. J. Biomed. Mater. Res. 21, 107, 1987.
36. Wood, N.K., Kaminski, E.J., and Oglesby, R.J. The significance of implant shape in experimental testing of biological materials: disc vs. rod. J. Biomed. Mater. Res. 4, 1, 1970.
37. Davila, J.C., Lautsch, E.V., and Palmer, T.E. Some physical factors affecting the acceptance of synthetic materials as tissue implants. Ann. N. Y. Acad. Sci. 146, 138, 1968.
38. Mendenhall, H.V. General surgical considerations. In: von Recum, A.F., ed. Handbook of Biomaterials Evaluation. New York: Macmillan, 1986, p. 252.
39. Klein, C.P.A.T., de Groot, K., Driessen, A.A., and van der Lubbe, H.B.M. A comparative study of different B-whitlockite ceramics in rabbit cortical bone with regard to their biodegradation behavior. Biomaterials 7, 144, 1986.
40. Visscher, O.E., Robison, R.L., Maulding, H.V., Fong, J.W., Pearson, J.E., and Argentieri, G.J. Note: biodegradation of and tissue reaction to poly(DL-lactide) microcapsules. J. Biomed. Mater. Res. 20, 667, 1986.
41. Christenson, L., Aebischer, P., and Galetti, P.M. Encapsulated thymic epithelial cells as a potential treatment for immunodeficiences. ASAIO 34, 681, 1988.
42. Christenson, L., Aebischer, P., McMillan, L., and Galletti, P.M. Tissue reaction to intraperitoneal polymer implants: species differences and effects of corticoid and doxorubicin. J Biomed. Mater. Res. 23, 705, 1989.
43. Marchant, R.E., Phua, K., Hiltner, A., and Anderson, J.M. In vivo biocompatibility studies. II. Biomer. preliminary cell adhesion and surface characterization studies, J. Biomed. Mater. Res. 18, 309, 1984.
44. Morello, J., Leitch, C., Nitz, S., Dyke, J.W., Andrusezeski, M., Maier, G., Ladau, W., and Beard, M. Detection of bacteremia by DIFCO ESP blood culture system. J. Clin. Microbiol. 32, 811, 1994.
45. Ostrovski, S. Achieving compliance in validation and metrology for cell and gene therapy. Biopharmaceuticals 8, 20, 1995.
46. Guideline on Sterile Drug Products Produced by Aseptic Processing. Washington, DC: U.S. Food and Drug Administration, Department of Health and Human Services, 1987.
47. United States Pharmacopeial Convention (1116). Microbiological Evaluation of Clean Rooms and Other Controlled Environments. Pharmacopeial Forum 21, 440, 1995.
48. du Moulin, G.C. Pitkin, Z., Shen, Y.J., Conti, E., Stewart, J.K., Charels, C., and Hamilton, D. Overview of a quality assurance/quality control compliance program consistent with PDA regulations and policies for somatic cell and gene therapies: a four-year experience. Cytotechnology 15, 365, 1994.
49. Center for Biologics Evaluation and Research. Points to Consider in the Collection, Processing, and Testing of ex vivo Activated Mononuclear Cells for Administration to Humans. Bethesda, MD: U.S. Food and Drug Administration, 1989.
50. Center for Biologics Evaluation and Research. Points to Consider in Human Somatic Cell Therapy and Gene Therapy. Bethesda, MD: U.S. Food and Drug Administration, 1991.
51. du Moulin, G.C. Use of the Limulus Amebocyte Lysate (LAL) assay in living cell therapies. Biopharm 5, 32, 1992.
52. ISO 10993. Parts 1-17. Biological Evaluation of Medical Devices. Geneva: International Organization of Standardization.
53. Hanson, D.J., and Upman, P.J. Histopathological Evaluation of Implanted Biomaterials using a Unique Scoring System. MD&D Conference/Expo., 1983.
54. Wallin, R.F., and Upman, P.J. Evaluating the biological effects of medical devices and materials. In: Encyclopedic Handbook of Biomaterials and Bioengineering. Vol. 1. 1995, pp. 399-432(part A).
55. Olson, M.E., Elri, H., Morck, D.W., and Lee, C.C. Biomaterials and the immune system. In: Encyclopedic Handbook of Biomaterials and Bioengineering. Vol. 1. 1995, pp. 433-467(part A).